Rein Therapeutics Inc.
RNTX
$0.92
-$0.03-2.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.16% | -48.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.10% | -27.91% | |||
| Operating Income | -32.10% | 27.91% | |||
| Income Before Tax | 82.14% | -485.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 81.74% | -472.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 81.74% | -472.78% | |||
| EBIT | -32.10% | 27.91% | |||
| EBITDA | -32.10% | 27.91% | |||
| EPS Basic | 82.39% | -415.97% | |||
| Normalized Basic EPS | -41.41% | 35.75% | |||
| EPS Diluted | 82.39% | -415.97% | |||
| Normalized Diluted EPS | -41.41% | 35.75% | |||
| Average Basic Shares Outstanding | 3.72% | 11.02% | |||
| Average Diluted Shares Outstanding | 3.72% | 11.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||